- By insider
CEO & President of Intercept Pharmaceuticals Inc (ICPT) Mark Pruzanski sold 35,000 shares of ICPT on 09/20/2016 at an average price of $165 a share. The total sale was $5.8 million.
Intercept Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in the development and commercialization of novel therapeutics to treat chronic liver disease utilizing its proprietary bile acid chemistry. Intercept Pharmaceuticals Inc has a market cap of $4.22 billion; its shares were traded at around $170.47 with and P/S ratio of 611.00. Intercept Pharmaceuticals Inc had an annual average EBITDA growth of 12.40% over the past 5 years.
-
Warning! GuruFocus has detected 4 Warning Signs with ICPT. Click here to check it out.
-
The intrinsic value of ICPT
CEO Recent Trades:
-
CEO & President Mark Pruzanski sold 35,000 shares of ICPT stock on 09/20/2016 at the average price of $165. The price of the stock has increased by 3.32% since.
Directors and Officers Recent Trades:
-
President of International Lisa Bright sold 246 shares of ICPT stock on 08/25/2016 at the average price of $159. The price of the stock has increased by 7.21% since.
For the complete insider trading history of ICPT, click here
.This article first appeared on GuruFocus.
-
Warning! GuruFocus has detected 4 Warning Signs with ICPT. Click here to check it out.
-
The intrinsic value of ICPT